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Novelty and Impact There is growing evidence to suggest EPLIN is a tumour 
suppressor molecule in several human cancers. The mechanisms governing this, 
however, are relatively unknown. This study provides insights into molecular 
associations which drive the regulatory actions of EPLIN, and establishes a broader 
picture of the signalling cascades co-ordinating cellular functions in prostate cancer. 
Developing a greater understanding of these cancer signalling systems will help 
elucidate better therapeutic strategies to prevent the progression of prostate cancer. 
  
Abstract 
EPLIN is frequently downregulated or lost in various cancers. The purpose of this 
study was to evaluate the importance of EPLIN in prostate cancer progression, with 
particular focus on the mechanistic implications to elucidate EPLIN’s tumour 
suppressive function in cancer. EPLIN expression was evaluated in prostate cancer 
cell lines and tissues. PC-3 and LNCaP EPLINα overexpression models were 
generated through transfection with EPLINα sequence and EPLIN knockdown was 
achieved using shRNA in CA-HPV-10 cells. Functional assays were performed to 
evaluate cellular characteristics and potential mechanisms were evaluated using a 
protein microarray, and validated using western blot analysis. EPLIN expression was 
reduced in clinical prostate cancer sections, including hyperplasia (p≤0.001) and 
adenocarcinoma (p=0.005), when compared to normal prostate tissue. EPLINα 
overexpression reduced cell growth, migration and invasion, and influenced 
transcript, protein and phosphoprotein expression of paxillin, FAK and Src. EPLIN 
knockdown increased the invasive and migratory nature of CA-HPV-10 cells and 
also induced changes to FAK and Src total and/or phospho expression.  Functional 
characterisation of cellular migration and invasion in addition to FAK and Src 
inhibition demonstrated differential effects between control and EPLINα 
overexpression and EPLIN knockdown cell lines. This study highlights that EPLIN 
expression in prostate cancer is able to influence several aspects of cancer cell 
characteristics, including cell growth, migration and invasion. The mechanism of the 
tumour suppressive action of EPLIN remains to be fully elucidated; and this study 
proposes a role for EPLIN’s ability to regulate the aggressive characteristics of 
prostate cancer cells partially through regulating FAK/Src signalling.  
 
Introduction 
 Prostate cancer is the second most common cancer in the UK and accounts for 
>11,000 cancer-related deaths (1). Epithelial protein lost in neoplasm (EPLIN) is a 
molecule that is frequently lost in cancer and has been implicated in the initiation of 
Epithelial Mesenchymal Transition (2), in addition to having tumour suppressive 
roles in cancer progression and development (2-6). 
 EPLIN was first reported in 1998 where differential expression was identified 
between normal epithelial cells and human papilloma virus (HPV) immortalized 
epithelial cells (7). EPLIN loss in cancer was demonstrated shortly after in oral, 
breast and prostate cancer (8). Subsequently, several publications have associated 
EPLIN to the progression and development of cancer (2, 4, 5, 9-11). EPLIN exists as 
two isoforms; a larger EPLINβ isoform consisting of 759 amino acids and a smaller 
EPLINα isoform of 600 amino acids (12). Although both isoforms display changes 
in expression in some cancers, the EPLINα isoform is generally considered more 
influential in cancer progression.  
Several studies have begun to explore the potential mechanisms of EPLIN in cancer 
cell-related functions. EPLIN is linked to Extracellular signal-regulated kinase 
(ERK) signalling where ERK phosphorylates EPLIN at various sites contributing to 
actin filament reorganisation and enhancing cell migration (13). Epidermal growth 
factor (EGF) promotes EPLIN protein turnover via phosphorylation, ubiquitination 
and degradation; processes also linked to ERK1/2 signalling (14). The tumour 
suppressive molecule p53 has also been established as an EPLIN-targeting molecule 
for transcription, where induction of EPLIN can influence cancer cell characteristics, 
including cell invasion (15). The human phosphatase CDC14A has been identified as 
an EPLIN-targeting molecule by dephosphorylating EPLIN at two ERK-targeting 
serine residues of EPLIN, counteracting the EGF-induced regulation of actin 
reorganisation, suggesting dynamic interplay of serine phosphorylation to drive 
EPLIN cell-related functions (16). Our lab and others have also established a 
potential link between EPLIN and paxillin, in addition to suggesting a role for 
EPLIN in the process of angiogenesis (4, 8, 11, 17). Taken together, EPLIN loss is 
likely to have significant effects on cellular functions including cellular migration, 
invasion and proliferation, thus exacerbating metastatic potential and cancer 
progression. 
In the current study we provide functional evidence that EPLIN is a negative 
regulator of prostate cancer and acts as a tumour suppressive molecule to impede 
metastatic traits. We provide additional evidence supporting the downregulation of 
EPLIN in clinical prostate cancer and demonstrate a potential mechanistic link 
between EPLINα and Proto-oncogene tyrosine-protein kinase (Src) / Focal adhesion 
kinase (FAK) signalling.  
  
Material and methods   
Cell lines and conditions 
Prostate cancer cell lines used for this study were purchased from ATCC 
(Middlesex, UK). PC-3, DU-145 and VCaP cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM / Ham’s F-12 with L-Glutamine) (Sigma-
Aldrich, Dorset, UK), supplemented with antibiotics (Sigma-Aldrich, Dorset, UK) 
and 10% foetal calf serum (Sigma-Aldrich, Dorset, UK).  LNCaP cells were cultured 
in RPMI-1640 medium (Sigma-Aldrich, Dorset, UK) supplemented with antibiotics 
(Sigma-Aldrich, Dorset, UK) and 10% foetal calf serum (Sigma-Aldrich, Dorset, 
UK). PZ-HPV-7 and CA-HPV-10 cells were cultured in keratinocyte serum free 
medium supplemented with 0.05mg/ml bovine pituitary extract and 5ng/ml EGF 
(Life Technologies, Paisley, UK). Cells were cultured at 37°C, 5% CO2 in a 
humidified incubator.  
 
Generation of prostate cancer cells overexpressing EPLINα.  
A plasmid containing the expression sequence for EPLINα was constructed to mimic 
the full length EPLINα sequence as described previously (5). The plasmid was 
verified and used to transfect PC-3 and LNCaP prostate cancer cells. Cells with 
increased EPLINα expression were designated PC-3/LNCaPEPLIN EXP, whilst control 
cells were designated PC-3/LNCaPpEF6. 
Knockdown of EPLIN using shRNA 
EPLIN was knocked down using shRNA purchased from Santa Cruz Biotechnology 
(Santa Cruz Biotechnology, Texas, United States) and was performed according to 
manufacturer’s instructions. Briefly, Solution A (containing shRNA plasmids) was 
mixed 1:1 with Solution B (containing Plasmid Transfection Reagent) and mixed by 
pipetting before being left to incubate for 45 minutes at room temperature. For each 
transfection, 800µl of Plasmid Transfection Medium was added and 200µl of the 
shRNA Plasmid DNA/shRNA Plasmid Transfection Reagent Complex (Solution A + 
Solution B) giving a final volume of 1000µl to each well. Cells were incubated with 
shRNA for 8 hours at 37° C in a 5% CO2 incubator. Following incubation, an 
additional 1000µl of cell media was added and left for a further 24 hours. Stable 
transfections were generated using puromycin selection at a concentration of 
2.5µg/ml and subsequently maintained in maintenance media containing 0.25µg/ml 
puromycin until required. 
 
RNA extraction, RT-PCR and cDNA synthesis 
RNA extraction was performed according to the TRI reagent protocol (Sigma-
Aldrich, Dorset, UK). RNA was reverse transcribed using a GoScript reverse 
transcription kit (Promega, Southampton, UK). Polymerase chain reaction (PCR) 
was subsequently performed to amplify EPLIN gene sequences using GoTaq Green 
Master Mix (Promega, Southampton, UK) and EPLIN specific primers (Table 1). 
Amplification conditions were as follows: 94°C for 5 min, 30 cycles of 94°C for 30s, 
55°C for 30 s and 72°C for 40 s and a final extension of 72°C for 10 minutes. 
Products were separated on a 1% agarose gel stained with SYBR Safe Gel Stain 
(Life Technologies, Paisley, UK). 
 
 
Protein extraction, quantification and western blotting 
Cells were grown in T75 cell culture flasks until approximately 90% confluency, 
detached, lysed in lysis buffer and centrifuged. Protein concentration was 
subsequently determined using a Bio-Rad DC protein assay kit (Bio-Rad 
Laboratories, Hemel-Hempstead, UK). Protein analysis was performed using a 
standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and antibody steps were performed using the SNAP id® 2.0 Protein Detection 
System (Merck Millipore Ltd., Feltham, UK). EPLIN antibody was obtained from 
Bethyl Laboratories (Montgomery, Texas, USA). GAPDH, p-FAK Y397, p-c-Src 
Y530, p-Paxillin Y31, p-paxillin Y118, and p-FAK Y925 were from Insight 
Biotechnology (Middlesex, UK).  Total paxillin and FAK were from BD Biosciences 
(BD Bioscience, Oxford, UK). C-Src and p-c-Src Y419 were from Abcam 
(Cambridge, UK). For knockdown experiments, FAK Y397, FAK Y925, paxillin 
Y31 and paxillin Y118 were obtained from Abcam (Cambridge, UK). Anti-mouse, 
anti-rabbit and anti-goat secondary antibodies were from Sigma-Aldrich (Dorset, 
UK). 
In vitro tumour cell functional assays 
Tumour cellular functional assays were performed to evaluate cellular proliferation, 
invasion and migration in PC-3 and LNCaP cells with manipulated EPLINα 
expression. Cell growth and invasion protocols were performed as previously 
reported (4). PC-3 cell migration was evaluated using a scratch/wound healing assay. 
PC-3 cells were seeded in a 24-well plate and allowed to reach confluence. Upon 
confluence, vertical scratches were made in the monolayer. Closure of the scratch 
was analysed over a 4 hour period under the microscope and images taken at 1 hour 
intervals. Cellular migration was calculated at each time point based on wound 
closure in comparison to the time 0 image. LNCaP cell migration was evaluated 
using a transwell migration assay. LNCaP cells were seeded at a density of 50,000 
cells into uncoated transwell inserts containing 8.0μm pores and placed into a 24 
well plate. Following a 3 day period, cells that migrated through the pores were fixed 
in formalin and stained using crystal violet. For the LNCaP invasion assay, cells 
were seeded at a density of 60,000 cells per well. Cellular invasion and migration 
was also determined in the presence of an FAK inhibitor (CAS4506-66-5) (Santa 
Cruz Biotechnology, Texas, United States) at a concentration of 5µM, and a Src 
inhibitor (dasatinib) (Axon Medchem, Groningen, Netherlands) at a concentration of 
500nM to determine the effect of EPLINα overexpression in conjunction with 
FAK/Src inhibition. For knockdown experiments, cellular migration and invasion 
was determined in control shRNA and EPLIN shRNA CA-HPV-10 cells. Cellular 
migration was evaluated using a transwell migration assay using the above protocol 
and a seeding density of 20,000 cells/well. For the invasion assay, the protocol was 
identical to the PC-3/LNCaP procedure also with a seeding density of 20,000 
cells/well. 
Protein microarray analysis 
Protein was extracted from PC-3EPLIN EXP and PC-3pEF6 cells and quantified by 
fluorometric protein quantification, as reported previously (18), and subsequently 
sent to KinexusTM Bioinformatics (Kinexus Bioinformatics, Vancouver, British 
Columbia, Canada). Data was analysed using several parameters including Globally 
Normalised Signal Intensity, Z ratio and % Change from Control (CFC). A Z ratio 
greater than 1.64 or less than -1.64 was considered significantly up- or down- 
regulated respectively. Molecules of interest were selected for validation using 
western blot analysis. 
Tissue Microarray (TMA) analysis of prostate cancer tissue  
Tissue Microarrays (TMA) were purchased to explore EPLIN expression in normal 
prostate tissue and prostate cancer tissue. TMA’s were purchased from US Biomax 
(US Biomax, Inc., Rockville, USA) and tissues were collected under HIPAA 
approved protocols by the manufacturer. TMA’s were stored and logged according 
to local HTA regulations. TMA1 was labelled HPro-Ade96Sur-01 and TMA2 was 
labelled PR8011a, according to the US Biomax reference numbers for each TMA.  
Immunohistochemistry (IHC)  
IHC was performed using anti-EPLIN antibody  and the Vectastain® Elite Universal 
ABC Kit (Vector Labs, UK). Antigen retrieval was performed with 0.1M EDTA 
buffer for 20 minutes/full power in the microwave. Slides were allowed to cool in 
running tap water, before being blocked for two hours with 5-10% horse serum, and 
then incubated with primary antibody (2µg/ml) overnight at 4°C. After incubation 
with secondary and tertiary reagents from the kit, slides were developed with DAB 
(diaminobenzidine) (5mg/ml) substrate (Sigma-Aldrich, Dorset, UK) for 10 minutes, 
counterstained with Gill’s haematoxylin, before being dehydrated, cleared in xylene 
and mounted in DPX (Sigma-Aldrich, Dorset, UK). Sections were visualized under a 
microscope and digital images were acquired. Staining intensities of EPLIN in each 
section were classified, by three independent researchers, as negative staining (0), 
weak staining (1), moderate staining (2) or strong staining (3) within epithelial 
components of the tissues. Staining intensities were subsequently aligned to 
patient/sample clinical information to identify differential staining patterns between 
groups. 
Statistical analysis 
Statistical analysis was performed using the SigmaPlot 11 (Systat Software Inc., 
London, UK) and Minitab 14 (Minitab Ltd., Coventry, UK) statistical software 
packages. Comparison between test groups was performed using a two sample, two 
tailed t-test or a Mann Whitney U test depending on data parameters. For PCR and 
western blot experiments, statistical significance was based on band intensities and 
was quantified using ImageJ software. All experiments were carried out a minimum 
of three independent times. Values of p < 0.05 were regarded as statistically 
significant.  
 
 
  
Results  
EPLIN expression is downregulated in prostate cancer cells 
EPLIN transcript and protein expression were evaluated in one prostate and five 
prostate cancer cell lines (Figure 1A). EPLIN transcript was expressed in all cell 
lines with high levels seen in DU-145, CA-HPV-10 and PZ-HPV-7. Lowest levels of 
EPLIN transcript were seen in cell lines PC-3, LNCaP and VCaP. EPLINβ transcript 
was expressed at lower levels and remained relatively consistent throughout the cell 
lines. Given the relatively consistent levels of EPLINβ transcript within all samples, 
it can be concluded that PC-3, LNCaP and VCaP also had lowest levels of EPLINα 
expression as well as total EPLIN transcript expression. For protein analysis, highest 
expression of EPLINα and β was seen in CA-HPV-10 and EPLINα was moderately 
expressed in PZ-HPV-7. Lower EPLINα expression was also seen for DU-145 and 
VCaP, whilst EPLINβ was negative in all cell lines except CA-HPV-10. For PC-3 
and LNCaP, both EPLIN isoforms were negative. For functional and mechanistic 
investigations, EPLINα expression was forced, utilising a construct coding for the 
alpha isoform only, in PC-3 and LNCaP cell lines and was knocked down in CA-
HPV-10 cells using shRNA. PCR and western blot analyses demonstrated a 
significant increase in EPLIN/EPLINα expression in PC-3EPLIN EXP and LNCaPEPLIN 
EXP in comparison to the respective PC-3pEF6 and LNCaPpEF6 controls (Figure 1B/C), 
and this was more apparent at the protein level. Interestingly, enhancements in 
EPLINβ protein levels were also observed in both PC-3 and LNCaP cells that had 
been transfected with the EPLINα expression plasmid. 
  
EPLIN expression is downregulated in prostate cancer tissue 
EPLIN protein expression in clinical prostate cancer tissues was determined using 
two tissue microarrays (TMA) (HPRo-Ade96Sur-01 and PR8011a). EPLIN 
expression was scored based on the epithelial staining intensity of the samples (0, 1, 
2, 3 representing, no, weak, moderate or strong staining respectively) by three 
independent researchers within each array. Patient clinical pathological information 
was considered alongside EPLIN expression. Within the first TMA (HPRo-
Ade96Sur-01), EPLIN expression was reduced in cancer tissue compared to normal 
tissue, though this did not reach statistical significance following analysis of the 
assigned staining intensities (p=0.153) (Figure 1D). EPLIN expression in normal 
tissue was predominately expressed in the epithelial portion of the sections. In a 
second TMA (PR8011a; Figure 1E) EPLIN expression was significantly reduced in 
patients with prostate cancer hyperplasia (p≤0.001) and adenocarcinoma (p=0.005) 
compared to normal prostate tissue. A significant reduction in EPLIN expression 
was also seen in prostate cancer hyperplasia samples compared to adjacent prostate 
tissue (p=0.003) and close to significant reductions were seen between adjacent 
tissue and adenocarcinoma (p=0.054), and between normal prostate tissue and 
chronic inflammation (p=0.071). No significant differences were seen between 
normal prostate tissues and adjacent prostate tissue (p=0.422).  
EPLIN loss in clinical prostate cancer was also seen following analysis of Gene 
Expression Omnibus (GEO) repositories from NCBI where EPLIN expression was 
significantly reduced in aggressive cancer tissues across several analyses (p<0.05) 
(Supplementary Figure 1A). In the HPRo-Ade96Sur-01 TMA, EPLIN staining 
intensities were also generally reduced in higher stage (Supplementary figure 1B)  
and Gleason score (Supplementary Figure 1C) cancers, though neither trends were 
statistically significant (p=0.229 and 0.853 respectively).  
EPLINα overexpression suppresses in vitro cell growth, migration and invasion of 
prostate cancer cells 
PC-3EPLIN EXP cells had a significantly reduced growth rate compared to PC-3pEF6 
cells at Day 3 (p=0.005) and at Day 5 (p=0.023) (Figure 2A). For the LNCaP cell 
line, a general reduction of cell growth was seen in LNCaPEPLIN EXP compared to 
LNCaPpEF6 cells, though significance was not reached (p=0.114 Day 3, p=0.329 Day 
5) (Figure 2B). Cell invasiveness was determined using a Matrigel invasion assay. 
PC-3EPLIN EXP cells were significantly less invasive than control PC-3pEF6 cells 
(p=0.048) (Figure 2C). Similarly LNCaPEPLIN EXP cells were less invasive than 
control LNCaPpEF6 cells, though this was not significant (p=0.194) (Figure 2D). 
Cellular migration was assessed using a wound healing assay and demonstrated a 
significant reduction in PC-3EPLIN EXP cells at the 2 hour (p=0.011), 3 hour (p=0.004) 
and 4 hour (p=0.005) time points, compared to PC-3pEF6 control cells (Figure 2E). A 
transwell migration assay was also performed using the LNCaP cell model (Figure 
2F) and revealed a general, though non-significant reduction of cellular migration in 
LNCaPEPLIN EXP cells compared to LNCaPpEF6 cells (p=0.381). 
EPLINα expression induces changes to paxillin and FAK 
expression/phosphorylation 
EPLINα overexpression increased the expression of FAK transcript in PC-3 and 
LNCaP cells lines, with a significant increase observed in PC-3EPLIN EXP cells 
compared to PC-3pEF6 controls (p=0.01) (Figure 3A). EPLINα overexpression had no 
effect on paxillin transcript expression in the PC-3 cell line, and significantly 
reduced paxillin in LNCaPEPLIN EXP compared to LNCaPpEF6 (p<0.001). EPLINα 
overexpression also induced several changes to FAK/paxillin phospho- and protein 
expression (Figure 3B). In the PC-3 cell model, EPLINα overexpression 
significantly increased the expression of pFAK Y925 (Supplementary Figure 2A; 
p=0.01), pPaxillin Y31 (Supplementary Figure 2B; p=0.031), total paxillin 
(Supplementary Figure 2C; p<0.001), and pPaxillin Y118 (Supplementary Figure 
2D; p=0.026) in comparison to control PC-3pEF6 cells. Increased expression of total 
FAK and pFAK Y397 were noted  in PC-3 cells following EPLINα overexpression, 
though these were not found to be significant (p>0.05). In the LNCaP cell model, 
EPLINα overexpression caused a significant increase in the expression of pFAK 
Y397 (Supplementary Figure 2E; p=0.036) and a significant reduction of pPaxillin 
Y118 (Supplementary Figure 2F; p=0.023) when compared to LNCaPpEF6 control 
cells. No significant differences between LNCaPpEF6 and LNCaPEPLIN EXP were seen 
for total FAK, pFAK Y925, total paxillin and pPaxilln Y31 (p>0.05).  
EPLINα may influence cellular migration and invasion partly through the action of 
FAK in PC-3 cells 
To explore the functional relationship between EPLINα and FAK, in vitro tumour 
invasion and migration assays were performed in PC-3 and LNCaP cells in the 
presence of an inhibitor known to inhibit FAK activity. For the invasion assay, 
treatment of PC-3pEF6 cells with 5µM FAK inhibitor significantly reduced cellular 
invasion (p=0.034 vs untreated PC-3pEF6 cells), but no significant differences were 
noted for PC-3EPLIN EXP cells (p>0.05 vs. untreated PC-3EPLIN EXP) (Figure 3C).  In 
LNCaP cells, FAK inhibition generally reduced cellular invasion of both LNCaPpEF6 
and LNCaPEPLIN EXP cells, but significance was not reached for either condition 
(Figure 3D).  
In PC-3pEF6 cells, treatment with FAK inhibitor (5μM) significantly reduced cellular 
migration, assessed using a wound healing assay, at 2, 3 and 4 hour time points 
(p=0.003, p=0.002 and p=0.001, respectively vs. untreated PC-3pEF6) (Figure 3E; 
Top). Treatment of PC-3EPLIN EXP cells with FAK inhibitor (5µM) lead to a 
significant decrease in cellular migration at 3 hours (p=0.034 vs. untreated PC-3EPLIN 
EXP cells), though no other significant differences were seen (p>0.05 vs untreated 
PC-3EPLIN EXP for hours 1, 2 and 4) (Figure 3E; bottom).  In LNCaPpEF6 (Figure 3F; 
top) and in LNCaPEPLIN EXP (Figure 3F; bottom) cells, FAK inhibition reduced cell 
migration, assessed using a transwell assay, though this impact was only found to be 
significant, in comparison to respective untreated controls, in LNCaPEPLIN EXP cells 
(p=0.01).  
EPLINα overexpression negatively regulates Src in prostate cancer cells 
A protein microarray was performed on PC-3pEF6 and PC-3EPLIN EXP cells to highlight 
molecules whose expression or phosphorylation status was influenced by forced 
expression of EPLINα. The protein microarray contained three pan-specific and two 
phospho-specific (Y529 and Y419) antibodies for Src. No significant differences 
between PC-3pEF6 and PC-3EPLIN EXP cells were seen in total Src expression or p-
SrcY529 expression, with Z-ratios remaining between 1.64 and -1.64. Of interest, a 
key Src activation site, Y419 was significantly down-regulated in PC-3EPLIN EXP cells 
compared to PC-3pEF6 cells (z-ratio < -1.64, Figure 4A). To further assess this 
relationship we sought to verify this trend using western blot analysis in PC-3 and 
LNCaP cell lines (Figure 4B). A decrease in band intensity for p-Src Y419 was seen 
which, following semi-quantitative analysis and normalisation to GAPDH, was 
found to be significantly downregulated in PC-3EPLIN EXP cells compared to PC-3pEF6 
cells (Figure 4C; p=0.005). A reduction of p-Src Y419 was also seen in LNCaPEPLIN 
EXP cells compared to LNCaPpEF6 cells, however this change was not statistically 
significant (p>0.05). In addition to p-Src Y419, total Src and p-Src Y530 were also 
tested. For both PC-3 and LNCaP cells, no significant differences were seen in total 
Src expression, which is in keeping with the results of the microarray. Contrary to p-
Src Y419, and partially to that of the protein microarray, p-Src Y530, a common site 
of dephosphorylation, was found to be enhanced via western blotting following 
EPLINα overexpression in PC-3 cells (Figure 4D; p=0.027 vs. PC-3pEF6 cells). In 
LNCaP, p-Src Y530 was also increased when EPLINα was overexpressed (Figure 
4B), however the increase didn’t quite reach significance following semi-quantitative 
band analysis and normalisation to GAPDH (p=0.068) (Figure 4E).  
Negative regulation of Src by EPLINα influences the invasive phenotype of prostate 
cancer cells 
To further elucidate the association of EPLINα and Src, two in vitro tumour cell 
functional assays were performed in the presence of a Src inhibitor (500nM 
dasatinib). In PC-3pEF6 cells, dasatinib treatment caused a significant reduction of 
cellular invasion (p<0.001 vs. untreated PC-3pEF6). However, this trend was not 
observed in PC-3EPLIN EXP cells, and treatment of dasatinib offered no further 
reductions in invasion in this cell line (p > 0.05 vs. untreated PC-3EPLIN EXP cells) 
(Figure 5A).  The impact of combined EPLINα overexpression and Src inhibition on 
PC-3 migration was also assessed using a scratch wound assay.  Dasatinib treatment 
caused a significant reduction in the migratory rates of PC-3pEF6 cells following a 4 
hour time period (p=0.004 vs. untreated PC-3pEF6 cells). In PC-3EPLIN EXP cells, 
cellular migration was also significantly reduced at the four hour time point when 
dasatinib was used, though not to as great an extent (p=0.012 vs. untreated PC-3EPLIN 
EXP cells) (Figure 5B).  The impact of dasatinib was also tested in the LNCaP cell 
model using an in vitro invasion assay and a transwell migration assay (Figure 
5C/D). For untreated LNCaP cells, EPLINα overexpression reduced cellular invasion 
as previously observed, and in this instance reached statistical significance (p=0.015 
vs LNCaPpEF6 cells) (Figure 5C). Dasatinib treatment caused a significant reduction 
in the cellular invasion of LNCaPpEF6 cells (p=0.016 vs. untreated LNCaPpEF6 cells) 
(Figure 5C). However, similar to the PC-3 model, treatment of LNCaPEPLIN EXP cells 
with dasatinib had no further significant effects on cellular invasion (p>0.05 vs. 
untreated LNCaPEPLIN EXP cells) (Figure 5C). Finally, dasatinib treatment 
significantly reduced the cellular migration of both LNCaPpEF6 cells and LNCaPEPLIN 
EXP cells (p<0.001 compared to respective untreated controls), but did not appear to 
have any differential effects between the two lines (Figure 5D).  
EPLIN knockdown in CA-HPV-10 cells influenced the expression Src and FAK 
EPLIN was knocked down in CA-HPV-10 cells using shRNA and the impact of 
EPLIN suppression was explored in relation to paxillin, FAK and Src expression 
(Figure 6). EPLIN transcript expression was significantly reduced using shRNA and 
verified by conventional PCR and semi-quantitative analysis (p=<0.001) (Figure 
6A). EPLINα protein expression was also significantly reduced and verified by 
western blotting and semi-quantitative analysis (p=0.004) (Figure 6B). No 
significant changes were seen in total paxillin, paxillin Y31, paxillin Y118, FAK 
Y925, total Src and Src Y530 following EPLIN knockdown in CA-HPV-10 cells 
(Figure 6C/D/E). However, EPLIN knockdown significantly increased the 
expression of total FAK in CA-HPV-10 cells (p=0.002) (Figure 6D/Supplementary 
Figure 3A) and appeared to increase the expression of FAK Y397 in CA-HPV-10, 
although significance was not reached (p=0.162) (Figure 6D/Supplementary Figure 
3B). EPLIN knockdown also significantly increased the expression of Src Y419 in 
CA-HPV-10 cells (p=0.008) (Figure 6E/Supplementary Figure 3C).  
Functional significance of EPLIN knockdown in CA-HPV-10 and links to FAK and 
Src   
The impact of EPLIN suppression individually and in conjunction with FAK or Src 
inhibition on cellular invasion (Figure 6F) and migration (Figure 6G) was explored 
in the CA-HPV-10 model. Knockdown of EPLIN brought about a significant 
increase in CA-HPV-10 cellular invasion (p=0.006). Inhibition of Src using dasatinib 
(500nM) has similar effects on both control and EPLIN knockdown CA-HPV-10 
cells, causing significant decreases in invasion in comparison to the relative 
untreated lines (both p=<0.001). Interestingly, the addition of an FAK inhibitor 
(5µM) had differential effects, having no significant effects on control CA-HPV-10 
cells but significantly reducing invasion in EPLIN knockdown CA-HPV-10 cells 
(p=0.017 vs. untreated EPLIN knockdown CA-HPV-10 cells) (Figure 6F). A similar 
trend was also observed in relation to cellular migration (Figure 6G). EPLIN 
knockdown significantly increased the migration of CA-HPV-10 cells using a 
transwell system (p=<0.001) and inhibition of Src induced significant decreases in 
migration in both CA-HPV-10 control and CA-HPV-10 EPLIN knockdown cells 
(both p=<0.001 vs. relative untreated equivalent). FAK inhibition again had 
differential impacts on CA-HPV-10 control and EPLIN knockdown cells, where no 
significant changes in migration were seen in control cells, whereas for CA-HPV-10 
EPLIN knockdown cells, cellular migration was significantly decreased when FAK 
was inhibited (p=0.004 vs. untreated CA-HPV-10 EPLIN knockdown cells) (Figure 
6G).  
Discussion 
Previous studies evaluating EPLIN in cancer progression have identified loss of 
EPLIN in aggressive cancer and suggest a regulatory role for EPLIN as a tumour 
suppressor (2, 4-6, 9, 10). Additionally, several mechanisms have been reported for 
the regulation of EPLIN expression, including ERK (13), EGF (14), DNp73 (19) and 
p53 (15) and provide important insight into how EPLIN may be regulated at a 
functional or expressional level. The aim of this study was to explore the importance 
of EPLIN in the progression and development of prostate cancer, with particular 
emphasis on elucidating mechanisms through which EPLIN inhibits prostate cancer 
progression to aid in the design of novel therapeutic strategies.  
Protein and transcript analysis in normal and cancerous prostate cell lines revealed 
EPLIN is differentially expressed in prostate cancer, with a reduction of EPLIN 
expression generally coinciding with aggressiveness of the cell line. This concurs 
with previous reports using PC-3 and LNCaP where EPLINα is lost in aggressive 
prostate cancer (8). We also explored the clinical implications of EPLIN expression 
suggesting that EPLIN expression is reduced or lost during progression of prostate 
cancer. Taken together with other studies (2, 4, 5, 10), our data suggests EPLIN 
could be useful as a potential prognostic marker for prostate cancer progression, 
however more in depth investigation, utilising larger cohorts are required to fully 
clarify this. 
Interestingly, following overexpression of EPLINα in the cellular based assays, we 
also saw an enhanced protein expression of EPLINβ. The exact reason for this is 
currently unknown, though, given that the expression sequence used in the cellular 
transfections does not contain coding regions for EPLINβ, nor did it significantly 
enhance the transcript expression of this isoform, we anticipate this may be a result 
of enhanced stabilisation or translation of the EPLINβ isoform. EPLINα 
overexpression reduced cellular growth of PC-3 cells, and this is in keeping with 
both in vitro and in vivo observations from a previous study conducted in the host 
laboratory (4). Previously, we have demonstrated a reduction of cellular growth in a 
sub cutaneous mouse model which corroborates our work detailed here on cellular 
proliferation (4). The work here substantiates EPLINα’s role as a suppressor of cell 
growth in prostate cancer (4) and other cancers including oesophageal cancer (10) 
and breast cancer (5). PC-3 and LNCaP EPLINα overexpression models were less 
able to infiltrate and invade a Matrigel membrane, an observation again in keeping 
with previous data in PC-3 (4) and LNCaP (2) models, and in lung and breast cancer 
(15) where EPLIN expression was able to influence cancer cell invasiveness. The 
migration assays in this study corroborates previous work elucidating EPLINα in 
tumour cellular migration in endothelial cells (11) and in breast cancer cells (5). 
Taken together, our current data supports a metastasis suppressive role for EPLINα 
in prostate cancer. Although future animal studies using in vivo metastasis models 
are needed to further explore the anti-metastatic impact of EPLIN in complex 
systems, this study highlights the potential for use in therapy to influence various 
cancer cell-related functions.   
The EPLIN interactome has only been explored briefly in the last decade, and the 
mechanisms governing how EPLIN exerts these tumour suppressive functions isn’t 
fully understood. As part of this study we aimed to explore the relationship between 
EPLINα, paxillin and FAK and the potential of such a relationship to drive the anti-
metastatic role of EPLINα. EPLINα overexpression influenced paxillin and FAK 
expression and also the phosphorylation of certain key residues within these 
proteins, such as FAK Y397/Y925 and paxillin Y31/Y118. These regions are critical 
to paxillin and FAK function and have implications for cellular migration and cancer 
progression (20). EPLINα overexpression enhanced paxillin phosphorylation at 
Y31/Y118 in PC-3 cells and phosphorylation within these residues have been 
associated with differential effects on cellular migration (21, 22), and hence reveals 
potential mechanisms through which EPLINα can regulate cellular migration. In 
contrast, LNCaP cells showed a reduction of paxillin Y118 following EPLINα 
overexpression and EPLIN suppression in CA-HPV-10 cells did not significantly 
influence paxillin or phospho-paxillin expression. If EPLIN can affect paxillin 
Y31/Y118 phosphorylation in cancer, depending on cell type, this could also lead to 
differential effects on paxillin:FAK association, thus resulting in changes to a 
number of cellular processes such as cellular migration and invasion (23). Whilst 
these findings are intriguing, care must be taken when interpreting the data, 
particularly for the LNCaP model, as there is a discrepancy between the paxillin 
transcript and protein effect following EPLIN overexpression, therefore further work 
is required to fully validate this link. FAK Y397  is a region of FAK crucial for 
controlling cellular functions, including cell survival and cellular migration (24), co-
ordinating interaction with regulatory proteins, like phosphoinositide 3-kinase 
(PI3K) (25), and is a major binding site for the SH2 domain of Src family kinases 
(26). Y925 is an established region of FAK and is important for cell migration, focal 
adhesion turnover and cell protrusion (27). Forced EPLINα expression also exerted 
differential effects of FAK Y397 and Y925 in the two cell lines tested, suggesting 
the EPLIN and FAK associations could be cell type specific. FAK inhibition using 
an FAK Y397 inhibitor was less effective at reducing cellular migration of PC-3 
cells overexpressing EPLINα, compared to PC-3pEF6 control cells, though this trend 
was not so clear in LNCaP cells. Interestingly, using a CA-HPV-10 knockdown 
model, differential effects on invasion and migration were again observed between 
control and EPLIN suppressed cells where inhibition of FAK in control cells, 
expressing higher levels of EPLIN, had no impact on invasion or migration, whereas 
in EPLIN knockdown cells, these traits were further reduced. Again similar to PC-3 
and LNCaP EPLIN overexpression cells, CA-HPV-10 EPLIN knockdown cells 
displayed generally higher levels of total FAK and FAK Y397. Whilst the 
expressional differences brought about by EPLIN overexpression or suppression are 
difficult to explain, the functional impact appears to be more consistent, suggesting 
that higher EPLIN expression exerts a level of negative regulation on FAK and 
subsequent loss of EPLIN removes such control, enhancing the sensitivity to FAK 
inhibition on migration and invasion. Whilst our data suggests that manipulation of 
EPLIN also impacts expressional and phosphorylation changes of FAK, the precise 
mechanism through which it brings about this effect appears complex, potentially 
arising due to differing cell models or differences in transfection efficiencies.  Taken 
together our data highlights a potential regulatory association between EPLIN,  FAK 
and paxillin however, further research is required to fully clarify this association and 
regulatory mechanism. It is particularly interesting to consider that EPLINα may also 
act upstream/downstream of FAK, potentially targeting this pathway at a number of 
points through its action on Src, a molecule which associates with FAK at Y397 to 
phosphorylate several other regions of FAK to propagate various signalling 
mechanisms (28, 29). The protein microarray demonstrated that EPLINα 
overexpression in PC-3 cells induced a reduction of Src Y419 phosphorylation, a 
region of Src considered to be the classical activation domain, associated with the 
progression of various cancers and linked to function and catalytic activity (30). This 
link was then explored using our CA-HPV-10 model, where knockdown of EPLIN 
increased the expression of Src Y419. Our current data suggests that EPLINα is a 
negative regulator of Src signalling, through direct or indirect 
phosphorylation/dephosphoylation of Src Y419 and/or Src Y530. Src is commonly 
elevated in cancer and is synergistic with paxillin and FAK, and propagation of this 
pathway is generally associated with cancer progression (31). Elevations in Src 
activity are also associated with activation of proteins involved in the mitogen 
activated protein kinase (MAPK) pathway to co-ordinate various cellular functions 
and control gene expression (32). In addition, Src phosphorylates β-catenin and 
suppresses the association of β-catenin with E-cadherin at adherens junctions, 
disrupting the integrity of adherens junctions and driving epithelial to mesenchymal 
transition (EMT) (33). EPLIN has previously been postulated as a suppressor of 
EMT in prostate cancer through the suppression of E-cadherin (2). Elevated Src 
activity in cancer is also linked to increased cellular invasion and progression-related 
events like EMT (34), influences actin dynamics and invasion (35) and has been 
implicated in cancer cell migration and invasion to a bone derived microenvironment 
(36). Src activity is also associated with cell cycle arrest (37), has implications on 
cellular functions in triple negative breast cancer (38) and has significance in 
prostate cancer progression (39). Finally, expression of Src is associated with FAK 
activity and specifically monitors focal adhesion dynamics to control cellular 
functions like migration and focal adhesion turnover (40, 41). Cells with altered 
focal adhesion turnover leads to less effective cellular migration, locomotion and 
spreading of cells, so this highlights potential mechanisms to which EPLIN can 
regulate cellular migration (42). The use of the dasatinib Src inhibitor partially 
corroborated these findings, particularly when evaluating EPLINα overexpression 
and Src activity in relation to cellular invasion where enhanced EPLINα expression 
reduced the anti-invasive impact of Src inhibition. However, unfortunately this trend 
was not replicated in the CA-HPV-10 knockdown model, where Src inhibition had 
similar effects on both control and EPLIN suppressed cells. These differences may 
have resulted due to the different model systems used. For example, enhancing the 
regulation through EPLIN overexpression, may bring about more significant effects 
than removal of this regulation through knockdown. Alternatively this may have 
arisen due to the differing nature and expressional profiles of the cell models 
themselves. Despite this, the current study has highlighted the ability of EPLIN 
manipulation to alter Src expression in the cell lines tested here.  Inhibition of Src is 
already an established area of therapeutics for cancer biology (43) and loss of EPLIN 
has previously been associated with enhanced chemoresistance to docetaxel and 
doxorubicin (2). Together, this presents interesting avenues of future work exploring 
the impact of EPLIN on cancer sensitivity to a range of chemotherapeutic agents and 
further scientific study of this relationship is warranted. 
The current study has demonstrated that EPLINα is able to regulate the expression 
and phosphorylation of paxillin, FAK and Src in prostate cancer, and in doing so 
potentially regulate a large number of cellular characteristics. However, key clinical 
questions remain, such as how to retain or replace EPLINα expression in aggressive 
cancer cells. This area of EPLIN biology remains in its infancy though recently it 
was reported that a small molecule inhibitor was able to enhance EPLINα protein 
expression, an effect linked to the suppressive action of p53 in cancer (15). 
Identification of compounds such as these and their use in conjunction with anti-
FAK/Src molecular therapies could represent promising novel therapeutic strategies. 
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Figure legends 
Figure 1 EPLIN expression in prostate cancer cells lines, confirmation of 
EPLINα overexpression in PC-3 and LNCaP cells, and clinical tissue staining in 
normal prostate and prostate cancer. (A) PCR (left) and western blot (right) 
analyses of wild-type prostate cell lines showing EPLIN, EPLINβ and GAPDH 
expression in PC-3, DU-145, LNCaP, VCaP, PZ-HPV-7 and CA-HPV-10 cells. (B) 
Verification of EPLIN transcript (left) and protein (right) overexpression in the PC-3 
cell model. (C) Verification of EPLIN transcript (left) protein (right) overexpression 
in the LNCaP cell model. Gel/blot images are representative of a minimum of three 
independent sample/repeats. For conciseness, composites are prepared using multiple 
gels/blots and representative GAPDH controls cropped and grouped together to 
represent overall trend. Comparative bands for individual molecules were taken from 
the same image. (D) EPLIN expression in normal prostate and in prostate cancer 
(TMA HPro-Ade96Sur-01). Representative images of EPLIN IHC staining from 
normal (n=8) and prostate cancer (n=36) samples at X20 objective magnification. 
(E) EPLIN expression in normal prostate, adjacent normal, chronic inflammation, 
hyperplasia and adenocarcinoma tissues (TMA PR8011a). Representative images of 
EPLIN IHC staining from normal prostate (n=8), adjacent normal (n=6), chronic 
inflammation (n=6), hyperplasia (n=26) and adenocarcinoma (n=30) tissue sections 
at X20 objective magnification. Respective boxplot representations show showing 
Median, Q1 and Q3 staining intensity scores and whiskers represent minimum and 
maximum staining intensity scores. ** = p≤0.01 and *** = p≤0.001. 
Figure 2 In vitro functional impact of EPLINα overexpression on PC-3 and 
LNCaP prostate cancer cell lines. (A) In vitro tumour cell growth assay in PC-
3pEF6  and PC-3EPLIN EXP cells at Day 3 and Day 5. (B) In vitro tumour cell growth 
assay in LNCaPpEF6 and LNCaPEPLIN EXP cells at Day 3 and Day 5. (C) In vitro 
tumour cell invasion assay in PC-3pEF6 and PC-3EPLIN EXP cells. (D) In vitro tumour 
cell invasion assay in in LNCaPpEF6 and LNCaPEPLIN EXP cells. (E) In vitro tumour 
cell wound healing assay in PC-3pEF6 and PC-3EPLIN EXP cells. Experiment recorded 
over 4 hours at 1 hour intervals. Cellular migration compared to Time 0 for PC-3pEF6 
and PC-3EPLIN EXP cells. (F) In vitro tumour cell transwell migration assay in in 
LNCaPpEF6 and LNCaPEPLIN EXP cells. Representative images for each experiment are 
shown. Bar charts represent mean of three independent repeats (n=3). Error bars 
represent SE of the Mean. * = p≤0.05, ** = p≤0.01. 
Figure 3 EPLINα regulation of paxillin and FAK in prostate cancer and 
functional significance in combination with an FAK inhibitor (A) PCR 
quantification of FAK and paxillin transcript expression in PC-3/LNCaPpEF6 and PC-
3/LNCaPEPLIN EXP. (B) Western blot analysis of total FAK/paxillin expression and 
FAK/paxillin phospho-protein expression in control and EPLINα overexpression cell 
lines. Molecules screened were total FAK, p-FAK Y397, p-FAK Y925, total 
paxillin, p-paxillin Y31 and p-paxillin Y118. Gel/blot images are representative of a 
minimum of three independent samples/repeats. For conciseness, composites are 
prepared using multiple gels/blots and representative GAPDH controls cropped and 
grouped together to represent overall trend. Comparative bands for individual 
molecules were taken from the same image (C) Effect of FAK inhibition in 
combination with EPLINα overexpression on cellular invasion in PC-3 cells. (D) 
Effect of FAK inhibition in combination with EPLINα overexpression on cellular 
invasion in LNCaP cells. (E) Effect of FAK inhibition in combination with EPLINα 
overexpression on cellular migration in PC-3 cells. Experiment recorded over 4 
hours at 1 hour intervals. Cellular migration compared to Time 0 for PC-3pEF6 and 
PC-3EPLIN EXP cells. (F) Effect of FAK inhibition in combination with EPLINα 
overexpression on cellular migration in LNCaP cells. FAK inhibition used at a 
concentration of 5µM. Experimental impact of FAK inhibition was run in 
conjunction with characterisation of EPLIN overexpression in PC-3 and LNCaP 
cells, hence values for untreated control and overexpression cells are presented again 
for comparison with equivalent cells treated with FAK inhibitor. Data represent 
mean of three independent repeats (n=3). Error bars represent SE of the Mean. * = 
p≤0.05, ** = p≤0.01, *** ≤ 0.001. 
Figure 4 Identification and validation of EPLINα interaction with Src. (A) 
Changes in Src expression detected by the Kinexus protein microarray when 
EPLINα is overexpressed. Data was analysed using Globally Normalised Signal 
Intensity and using the Z-ratio. Significance was determined using the Z-ratio; a z-
ratio of > 1.64 or < -1.64 was deemed statistically significant. (B) Validation of Src 
and p-Src expression in control and EPLINα overexpression PC-3 and LNCaP cell 
lines. Molecules verified were total Src, p-Src Y419 and p-Src Y530. Gel/blot 
images are representative of a minimum of three independent samples/repeats. For 
conciseness, composites are prepared using multiple gels/blots and representative 
GAPDH controls cropped and grouped together to represent overall trend. 
Comparative bands for individual molecules were taken from the same image. (C) 
Semi-quantitative analysis of p-Src Y419 expression in PC-3pEF6 and PC-3EPLIN EXP. 
(D) Semi-quantitative analysis of p-Src Y530 expression in PC-3pEF6 and PC-3EPLIN 
EXP. (E) Semi-quantitative analysis of p-Src Y530 expression in LNCaPpEF6 and 
LNCaPEPLIN EXP. GAPDH was used alongside validation experiments as a control 
and to normalise protein expression. Bar charts represent mean of three independent 
repeats (n=3). Error bars represent SE of the Mean.* = p≤0.05, ** = p≤0.01.  
Figure 5 Functional impact of EPLINα overexpression and Src inhibition on 
PC-3 and LNCaP cell migration and invasion. (A) PC-3 invasion assay with Src 
inhibitor. Representative images of PC-3pEF6 and PC-3EPLIN EXP cells with/without src 
inhibitor at concentration 500nM. (B) PC-3 migration/wound healing assay with Src 
inhibitor. Representative images of PC-3pEF6 and PC-3EPLIN EXP cells (x20 
magnification) at 0 hour and 4 hours of scratch assay, with/without src inhibitor. (C) 
LNCaP invasion assay with Src inhibitor. Representative images of LNCaPpEF6 and 
LNCaPEPLIN EXP cells (x20 magnification) with/without src inhibitor. (D) LNCaP 
transwell migration assay with Src inhibitor. Representative images of LNCaPpEF6 
and LNCaPEPLIN EXP cells with/without src inhibitor. Bar charts represent mean of 
three independent repeats (n=3). Error bars represent SE of the Mean.* = represents 
p≤0.05, ** = p≤0.01 and *** = p≤0.001. 
Figure 6 EPLIN knockdown using shRNA in CA-HPV-10 cells and associations 
with paxillin, FAK and Src. (A) Verification of EPLIN transcript knockdown by 
PCR. Semi-quantitative analysis shown using Image J software and knockdown 
depicted as % control. (B) Verification of EPLIN protein knockdown by western 
blotting. Semi-quantitative analysis shown using Image J software and knockdown 
depicted as % control. (C) Western blot of the effect of EPLIN knockdown in CA-
HPV-10 on the expression of paxillin, paxillin Y31 and paxillin Y118. (D) Western 
blot of the effect of EPLIN knockdown in CA-HPV-10 on the expression of total 
FAK, FAK Y397, FAK Y925. (E) Western blot of the effect of EPLIN knockdown 
in CA-HPV-10 on the expression of total Src, Src Y419, Src Y530. Gel/blot images 
are representative of a minimum of three independent samples/repeats. For 
conciseness, composites are prepared using multiple gels/blots and representative 
GAPDH controls cropped and grouped together to represent overall trend. 
Comparative bands for individual molecules were taken from the same image. (F) 
Effect of EPLIN knockdown in conjunction with FAK or Src inhibition on CA-
HPV-10 cellular invasion. (G) Effect of EPLIN knockdown in conjunction with 
FAK or Src inhibition on CA-HPV-10 cellular migration.  Bar charts shown 
represent mean values of a minimum of three independent repeats. Error bars 
represent SE of the Mean. * p = ≤0.05, ** p = ≤0.01, *** p = ≤0.001. 
Supplementary Figure 1 EPLIN Gene Expression Omnibus (GEO) profiles and 
EPLIN IHC staining of EPLIN corresponding the cancer stage and Gleason 
score. (A) Profile GDS2865 / 217892_s_at; EPLIN score value in poorly metastatic 
tissue and highly metastatic tissue (top). Profile GDS1439 / 222457_s_at; EPLIN 
score value in benign prostate tissue, primary prostate cancer and metastatic prostate 
cancer (bottom). Cohorts extracted from NCBI GEO database. (B)  Boxplot 
representations showing Median, Q1 and Q3 staining intensity. Box plot data shows 
Stage II (n=7) vs. combined Stage III and IV (n=29). Whiskers represent minimum 
and maximum staining intensity. (C) Boxplot representations of Median, Q1 and Q3 
staining intensity scores. Box plot data shows combined Gleason 6/7 (n=14) vs. 
combined Gleason 8/9/10 (n=22). Whiskers represent minimum and maximum 
staining intensity. * = represents p≤0.05, ** = p≤0.01 and *** = p≤0.001. 
Supplementary Figure 2 Semi-quantitative analysis of western blot protein 
bands shown in Figure 3 with significant differences following EPLIN 
overexpression. (A) pFAK Y925 expression in PC-3pEF6 and PC-3EPLIN EXP cells 
following semi-quantitative analysis and normalisation to GAPDH. (B) Paxillin Y31 
expression in PC-3pEF6 and PC-3EPLIN EXP cells following semi-quantitative analysis 
and normalisation to GAPDH. (C) Paxillin expression in PC-3pEF6 and PC-3EPLIN EXP 
cells following semi-quantitative analysis and normalisation to GAPDH. (D) 
pPaxillin Y118 expression in PC-3pEF6 and PC-3EPLIN EXP cells following semi-
quantitative analysis and normalisation to GAPDH. (E) pFAK Y397 expression in 
LNCaPpEF6 and LNCaPEPLIN EXP cells following semi-quantitative analysis and 
normalisation to GAPDH. (F) pPaxillin Y118 expression in LNCaPpEF6 and 
LNCaPEPLIN EXP cells following semi-quantitative analysis and normalisation to 
GAPDH. Bar charts represent the mean average of band intensity of three 
independent repeats (n=3). Error bars represent SE of the Mean. * = p≤0.05, ** = 
p≤0.01 and *** = p≤0.001. 
Supplementary Figure 3 Semi-quantitative analysis of western blot protein 
bands shown in Figure 6 with significant or notable differences following 
EPLIN knockdown. (A) FAK expression in CA-HPV-10 cells transfected with 
control shRNA or EPLIN shRNA following semi-quantitative analysis and 
normalisation to GAPDH. (B) FAK Y397 expression in CA-HPV-10 cells 
transfected with control shRNA or EPLIN shRNA following semi-quantitative 
analysis and normalisation to GAPDH. (C) Src Y419 expression in CA-HPV-10 
cells transfected with control shRNA or EPLIN shRNA following semi-quantitative 
analysis and normalisation to GAPDH. Bar charts shown represent mean values of a 
minimum of three independent repeats. Bar charts are represented as 
percentage/control. Error bars represent SE of the Mean. * = p≤0.05, ** = p≤0.01 
and *** = p≤0.001. 
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